Studies of suloctidil in experimental thrombosis in baboons.
Suloctidil has been evaluated in the baboon for its antithrombotic efficacy using models of both acute and chronic arterial thrombogenesis. Acute thrombus formation was initiated by Dacron vascular grafts inserted as extension segments into chronic arteriovenous shunts. 111In-platelet deposition was measured by scintillation camera imaging for one hour. The results after oral administration of suloctidil (100 mg/kg/d in two divided doses) were not different from control studies. Moreover, concurrent heparin anticoagulation did not affect 111In-platelet deposition compared with control data. In contrast, ticlopidine (20 mg/kg/d) significantly decreased platelet deposition that was reduced further by the addition of heparin. Chronic arterial-thromboembolism was initiated by segments of polyurethane (Biomer) cannula introduced into chronic arteriovenous shunts. Thrombus formation by the polyurethane cannula was measured as 111In-platelet turnover (corrected for removal of senescent platelets). Cannula platelet consumption was unaffected by suloctidil (20 mg/kg/d given in two divided doses for two days preceding and throughout the period of platelet survival measurement). In contrast, dipyridamole (10 mg/kg/d) and sulfinpyrazone (100 mg/kg/d) completely interrupted cannula platelet consumption. We conclude that suloctidil probably has little or no effect on platelet-dependent thrombus formation.
D000208:Acute Disease; D000818:Animals; D001792:Blood Platelets / Q000502:physiology; D002908:Chronic Disease; D004195:Disease Models, Animal; D007204:Indium; D007700:Kinetics; D008297:Male; D010215:Papio; D010976:Platelet Count; D011412:Propanolamines / Q000627:therapeutic use*; D011868:Radioisotopes; D013468:Suloctidil / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy*
D011412:Propanolamines; D011868:Radioisotopes; D007204:Indium; D013468:Suloctidil